溶解性 |
|
存贮条件 | 储存温度-20°C |
产品介绍 | Empagliflozin (BI 10773)是一种有效的,选择性SGLT-2抑制剂,IC50为3.1 nM,比作用于SGLT-1, 4, 5和6选择性高300倍以上。Phase 3。 |
生化机理 |
Empagliflozin is a potent, selective sodium glucose co-transporter-2 inhibitor that is in development for the treatment of type 2 diabetes. Empagliflozin is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), which is found almost exclusively in the proximal tubules of nephronic components in the kidneys. SGLT-2 accounts for about 90 percent of glucose reabsorption into the blood. Blocking SGLT-2 causes blood glucose to be eliminated through the urine via the urethra. The Empagliflozin phase III clinical trial program will include about 14,500 patients. The program consists of twelve ongoing international phase III clinical trials, including a large cardiovascular outcomes trial. |
别名 | 依帕列净;(1S)-1,5-脱水-1-C-[4-氯-3-[[4-[[(3S)-四氢-3-呋喃基]氧基]苯基]甲基]苯基]-D-葡萄糖醇;BI-10773;BI 10773;BI10773;BI 10773; (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol |